


What is claimed is:

1. A compound of Formula I, or a pharmaceutical salt thereof,

5



(I)

in which

10

R₁ is CH₃, CF₃, or Cl;

R₂ is F, Cl, OR', or H;

R₃, R₄, and R₅ are independently H, F, Cl, Br, C₃₋₆cycloalkyl, OR', -N(C₁₋₆alkyl)₂, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkyl (optionally substituted with up to seven fluorine atoms, up to one hydroxy, up to one -N(C₁₋₆alkyl)₂, and up to one -OC₁₋₆alkyl); provided not all R₃, R₄, and R₅ are hydrogen simultaneously.

15

R₆ is H or F;

R' is independently H or C₁₋₆ alkyl optionally substituted with up to seven fluorine atoms.

20

2. A compound or a pharmaceutically acceptable salt of thereof of claim 1 in which

R₁ is CH₃ or CF₃;

R₂ is H;

R₃ is F;

25

R₄ is CH₃, Cl, Br, vinyl, CF₃, F, or H;

R₅ is F or H; and

R₆ is H.

3. The compound of claim 2 that is (2R,3S,4S,5S,6R)-2-((R)-(3',5'-Difluoro-3,4'-dimethyl-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
- 5 4. The compound of claim 2 that is (2R,3S,4S,5S,6R)-2-((R)-(4'-Chloro-3',5'-difluoro-3-methyl-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
5. The compound of claim 2 that is (2R,3S,4S,5S,6R)-2-((R)-(4'-Bromo-3',5'-difluoro-3-methyl-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
- 10 6. The compound of claim 2 that is (2R,3S,4S,5S,6R)-2-((R)-(3',5'-Difluoro-3-methyl-4'-vinyl-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
- 15 7. The compound of claim 2 that is (2R,3S,4S,5S,6R)-2-((R)-(3'-Fluoro-3-methyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
- 20 8. The compound of claim 2 that is (2R,3S,4S,5S,6R)-2-((R)-(3'-Fluoro-3-methyl-5'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
- 25 9. The compound of claim 2 that is (2R,3S,4S,5S,6R)-2-((R)-Hydroxy(3',4',5'-trifluoro-3-methyl-[1,1'-biphenyl]-4-yl)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
10. The compound of claim 2 that is (2R,3S,4S,5S,6R)-2-((R)-(3',5'-Difluoro-3-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
- 30 11. The compound of claim 2 that is (2R,3S,4S,5S,6R)-2-((R)-(3',5'-Difluoro-3-methyl-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.

12. A compound or a pharmaceutically acceptable salt thereof recited in any one of claims 1-11 for use as a medicament.
- 5 13. A compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11 for use in the prevention or treatment of a disease or condition ameliorated by the inhibition of FimH function or activity.
- 10 14. A compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11 for use in the prevention or treatment of a bacterial infection, Crohn's disease (CD), and Inflammatory Bowel Disease (IBD).
- 15 15. A compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11 for use in the prevention or treatment of urinary tract infection (UTI).
- 16 16. A compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11 for use in the manufacture of a medicament for the prevention or treatment of a disease or condition ameliorated by the inhibition of FimH function or activity.
- 20 17. A compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11 for use in the manufacture of a medicament for the prevention or treatment of a bacterial infection, Crohn's disease (CD), and Inflammatory Bowel Disease (IBD).
- 25 18. A compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11 for use in the manufacture of a medicament for the prevention or treatment of urinary tract infection.
- 30 19. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11 together with a pharmaceutically acceptable carrier.
20. A method of inhibition of FimH function comprising contacting FimH with a compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11.

21. A method of treatment of a FimH-mediated disease comprising the administration of a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11 to a human patient in need thereof.
- 5
22. The method as recited in claim 21 wherein said disease is chosen from a bacterial infection, Crohn's disease (CD), and Inflammatory Bowel Disease (IBD).
23. The method as recited in claim 22 wherein said bacterial infection is a urinary tract
- 10 infection.
24. The method as recited in claim 23 wherein said urinary tract infection is recurrent.
25. The method as recited in claim 23 wherein said urinary tract infection is chronic.
- 15
26. The method as recited in claim 22 wherein said bacterial infection is an antibiotic-resistant bacterial infection.
27. The method as recited in claim 22 wherein said disease is Crohn's disease.
- 20
28. A method of treatment of a FimH-mediated disease comprising the administration of:
- a. a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof as recited any one of claims 1-11; and
- b. another therapeutic agent.
- 25
29. The method as recited in claim 28 wherein said disease is Urinary Tract Infection.
30. The method as recited in claim 28 wherein said disease is Crohn's Disease.
- 30
31. The method as recited in claim 28 wherein said disease is Inflammatory Bowel Disease.

32. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11 formulated for oral (PO) administration.
- 5 33. The pharmaceutical composition as recited in claim 32, wherein said composition is chosen from a tablet and a capsule.
34. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as recited in any one of claims 1-11 formulated for topical
10 administration.